PSA Standardization
Effect on "Watchful Waiting"
October 2009
Visually we can see this difference again in the figure shown. After some amount of time a man’s PSA becomes elevated or greater than the 4.0 ng/mL cutoff with a Hybritech assay. Using that same cutoff in a WHO standardized assay, the PSA is now less than 4.0 ng/mL or may be considered “normal”. After some period of time, perhaps an abnormal result would be obtained but if the increase in PSA is due to cancer there is a greater risk in increasing the stage and grade of prostate cancer with the watchful waiting approach.
Watchful Waiting |
Jump to section:
- Introduction
- Elevated PSA Result on Screening
- Reasons for Ordering PSA1
- PSA Screening in the News
- Recommendations for Screening
- Arguments for Screening for Prostate Cancer
- Recommendations for Not Screening
- Arguments Against Screening for Prostate Cancer
- PSA Sensitivity and Specificity
- High-Grade Prostate Cancer is Not Rare When PSA =4.0 ng/mL6
- Increase Specificity Using PSA Velocity8
- Optimizing Clinical Sensitivity and Specificity: Age/Ethnic Reference Intervals9,10
- Utilization of Free/Total PSA Ratio11
- Why Aren't PSA Results Interchangeable?
- Development of PSA Standards
- Development of PSA Standards
- Effect of Analytical Bias on Classification Based on Fixed Criteria
- Analytical Difference: Results per 1000 Patients Tested13
- Hybritech vs. WHO Standardized Assays12,14
- Analytical Differences15
- CAP Proficiency Testing
- WHO 96/670 Total PSA Preparations16
- WHO Calibration/Concordance at 3.1 ng/mL Cutoff5
- WHO Calibration/Concordance at 3.1 ng/mL Cutoff5
- WHO Calibration/Concordance at 4.0 ng/mL Cutoff5
- Clinical Differences in PSA Screening14
- The Clinical Difference
- Fixed Thresholds Produce Problems for Biopsy Recommendations
- Effect on "Watchful Waiting"
- Effect on "Watchful Waiting"
- Adding Biological Variability into the Mix
- Futures in Prostate Cancer Testing?
- PSA Testing at Mayo
- Conclusions
- References
- References
- Questions?


